share_log

In-Depth Examination Of 14 Analyst Recommendations For Apellis Pharmaceuticals

アペリスファーマシューティカルズの14人のアナリスト推奨株式の詳細調査

Benzinga ·  05/08 14:00

In the latest quarter, 14 analysts provided ratings for Apellis Pharmaceuticals (NASDAQ:APLS), showcasing a mix of bullish and bearish perspectives.

The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings81500
Last 30D20000
1M Ago40200
2M Ago00100
3M Ago21200

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $77.14, with a high estimate of $92.00 and a low estimate of $52.00. This upward trend is apparent, with the current average reflecting a 12.2% increase from the previous average price target of $68.75.

price target chart

Exploring Analyst Ratings: An In-Depth Overview

An in-depth analysis...

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする